AAM
XENE icon

Advisors Asset Management’s Xenon Pharmaceuticals XENE Stock Holding History

Advisors Asset Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$405K Sell
6,961
-1,051
-13% -$48.4K 0.01% 1012
2025
Q4 		$359K Sell
8,012
-3,452
-30% -$145K 0.01% 1025
2025
Q3 		$460K Sell
11,464
-741
-6% -$26.1K 0.01% 988
2025
Q2 		$382K Sell
12,205
-2,076
-15% -$67.7K 0.01% 1000
2025
Q1 		$479K Buy
14,281
+1,233
+9% +$46.8K 0.01% 938
2024
Q4 		$511K Sell
13,048
-544
-4% -$22.5K 0.01% 923
2024
Q3 		$535K Buy
13,592
+493
+4% +$19.9K 0.01% 912
2024
Q2 		$511K Sell
13,099
-618
-5% -$24.7K 0.01% 894
2024
Q1 		$591K Buy
13,717
+3,301
+32% +$152K 0.01% 865
2023
Q4 		$480K Buy
10,416
+228
+2% +$8.06K 0.01% 901
2023
Q3 		$348K Buy
10,188
+2,096
+26% +$78.4K 0.01% 994
2023
Q2 		$312K Sell
8,092
-300
-4% -$11.9K 0.01% 1040
2023
Q1 		$300K Buy
8,392
+546
+7% +$20.2K 0.01% 1040
2022
Q4 		$309K Buy
7,846
+3,725
+90% +$136K 0.01% 1049
2022
Q3 		$149K Sell
4,121
-927
-18% -$33.3K ﹤0.01% 1193
2022
Q2 		$154K Buy
5,048
+2,900
+135% +$87.7K ﹤0.01% 1210
2022
Q1 		$66K Buy
+2,148
New +$64.3K ﹤0.01% 1387

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Advisors Asset Management's XENE Position: Q1 2026 in Review

Advisors Asset Management reduced its Xenon Pharmaceuticals (XENE) stake by 13% in Q1 2026, selling an estimated $48.4K and leaving 6,961 shares worth $405K. The position accounts for 0.01% of the portfolio, ranked #1012.

Advisors Asset Management first reported a position in XENE in Q1 2022 and has held it in 17 quarters since. The position peaked at $591K in Q1 2024. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • Advisors Asset Management held 6,961 shares of Xenon Pharmaceuticals worth $405K as of Q1 2026.
  • Advisors Asset Management sold 1,051 Xenon Pharmaceuticals shares in Q1 2026, an estimated $48.4K.
  • Xenon Pharmaceuticals made up 0.01% of Advisors Asset Management's portfolio in Q1 2026, its #1012 holding.
  • Advisors Asset Management first reported a position in Xenon Pharmaceuticals in Q1 2022 and has held it in 17 quarters since.
  • Advisors Asset Management's Xenon Pharmaceuticals position peaked at $591K in Q1 2024.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Advisors Asset Management's 13F filing for Q1 2026, filed 15 May 2026.